Panbela Therapeutics Q1 2023 Earnings Report $0.41 +0.04 (+10.51%) As of 01/21/2025 03:51 PM Eastern Earnings HistoryForecast Panbela Therapeutics EPS ResultsActual EPS-$390.40Consensus EPS -$294.20Beat/MissMissed by -$96.20One Year Ago EPSN/APanbela Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APanbela Therapeutics Announcement DetailsQuarterQ1 2023Date5/4/2023TimeN/AConference Call ResourcesPBLA Earnings History Panbela Therapeutics Earnings HeadlinesPanbela Therapeutics Announces Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comPanbela Therapeutics, Inc.: Panbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 15, 2024 | finanznachrichten.deThe #1 Stock for Trump’s Second Term?Imagine how much money you could make if you bought all of the top performing stocks during Trump's second term? Well, legendary investor Louis Navellier's stock rating system... Gave a buy rating to ALL of the top 30 performing stocks in the S&P 500 index of Trump's first term...January 22, 2025 | InvestorPlace (Ad)Panbela Therapeutics Inc (PBLA) Q3 2024 Earnings Call Highlights: Strategic Loan and Clinical ...November 15, 2024 | finance.yahoo.comPanbela Therapeutics, Inc. (PBLA) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comPanbela Provides Business Update and Reports Q3 2024 Financial ResultsNovember 14, 2024 | globenewswire.comSee More Panbela Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Panbela Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Panbela Therapeutics and other key companies, straight to your email. Email Address About Panbela TherapeuticsPanbela Therapeutics (NASDAQ:PBLA), a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.View Panbela Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings CSX (1/23/2025)Intel (1/23/2025)Texas Instruments (1/23/2025)Freeport-McMoRan (1/23/2025)General Electric (1/23/2025)Union Pacific (1/23/2025)Elevance Health (1/23/2025)Verizon Communications (1/24/2025)NextEra Energy (1/24/2025)American Express (1/24/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
